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M ultiple influences on human lung growth and develop-ment occur, beginning with preconception exposuresand continuing through conception and childhood into
early adulthood (Figure). Numerous environmental exposures (both
positive and negative) accumulate along this pathway, and their sum
determines lung health and disease. Many studies of perinatal and
pediatric lung health and disease have focused on very premature
neonates, a population most likely to have aberrant physiology, acute
lung injury, or other medical comorbidities in addition to long-term
lung disease. However, there is a great need to better delineate the
normal trajectories of lung growth and development throughout the
lifespan among most infants who are delivered at term or late pre-
term and to identify the environmental influences that may posi-
tively or negatively affect lung development. Although evidence sug-
gests correlations between infant lung health and adult lung function,
significant knowledge gaps exist regarding the influence of the pre-
conception, perinatal, and postnatal periods on general lung health
throughout life.1
On October 1 and 2, 2015, the National Heart, Lung, and Blood
Institute convened a group of extramural investigators to develop
recommendations for the direction(s) of future research in prena-
tal and perinatal determinants of lung health and disease in early life
and to identify opportunities for scientific advancement. Work-
shop participants were divided into working groups that focused on
4 areas of lung development research: (1) lung development and
function in infants that influence the trajectory to health and dis-
ease; (2) pregnancy abnormalities that disturb lung development;
(3) preconception, prenatal, and postnatal developmental program-
ming; and (4) maternal, fetal, infant, and childhood environmental
exposures. Each subgroup reviewed the current state of the sci-
ence, identified gaps in knowledge, and offered specific recommen-
dations for future research. This report provides a summary of the
workshop participants’ discussion and recommendations as well as
the priorities they identified for future research in prenatal and peri-
natal influences on lung growth and development (Table).
Lung Development and Function in Infants
Normal lung development consists of a series of carefully orches-
trated events. Longitudinal studies of lung development and func-
tion indicate that, in most cases, an individual’s pulmonary function
follows a predictable progression from birth through childhood and
early adulthood until full maturation at age 22 years.1-3 Subsequent
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throughout life. On October 1 and 2, 2015, the National Heart, Lung, and Blood Institute
convened a group of extramural investigators to develop their recommendations for the
direction(s) for future research in prenatal and perinatal determinants of lung health and
disease in early life and to identify opportunities for scientific advancement. They identified
that future investigations will need not only to examine abnormal lung development, but also
to use developing technology and resources to better define normal and/or enhanced lung
health. Birth cohort studies offer key opportunities to capture the important influence of
preconception and obstetric risk factors on lung health, development, and disease. These
studies should include well-characterized obstetrical data and comprehensive plans for
prospective follow-up. The importance of continued basic science, translational, and animal
studies for providing mechanisms to explain causality using new methods cannot be
overemphasized. Multidisciplinary approaches involving obstetricians, neonatologists,
pediatric and adult pulmonologists, and basic scientists should be encouraged to design and
conduct comprehensive and impactful research on the early stages of normal and abnormal
human lung growth that influence adult outcome.
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gradual age-related declines also generally follow a predictable
pattern.3 Those individuals who begin in the lowest quartile of lung
function as an infant are typically in the lowest quartile of lung func-
tion as an adult.1 Individuals in the lower quartile are most suscep-
tible to lung-related disease later in life, probably because of a fail-
ure to achieve maximum adult airflow and vital capacity, resulting in
premature loss of the physiological respiratory reserves.2,3 Lange et
al3 reported that diminished airway function (a forced expiratory vol-
ume in the first second of expiration <80% predicted) after birth was
associated with adult respiratory disease and that accelerated lung
function decline (loss of forced expiratory volume in the first sec-
ond of expiration) later in life was not a required feature of chronic
obstructive pulmonary disease. However, multiple aspects of nor-
mal lung development, including developmental trajectories, are
poorly understood and could be informed by well-designed
longitudinal cohort studies.
Furthermore, any adverse exposures prior to or during devel-
opment (prenatal, postnatal, childhood, and/or adolescence) have
the potential to change the trajectory of lung development as well
as the loss of lung function with age.3 The best-studied example is
infection.4,5 Lower respiratory illness in early life has been associ-
ated with diminished airway function during early life and, subse-
quently, an increased risk of chronic obstructive pulmonary dis-
ease in late adult life.6 Even 1 episode of a pediatric respiratory illness
(eg, pneumonia or respiratory syncytial virus) may decrease levels
of lung function, affect the long- term developmental trajectory, and
increase the susceptibility to obstructive lung disease and other com-
plications as an adult.4,5 Again, preconceptional and early life stud-
ies in selected populations are needed to identify the early life modi-
fiers that affect initial lung health trajectories and mediate disease
susceptibility.
Techniques for noninvasive longitudinal measurement of air-
way anatomy and lung mechanics are needed to best evaluate the
stimuli and insults that affect initial and long-term trajectories of lung
health and disease. Evaluation of neonatal lung function has been
challenging because conventional pulmonary function tests (spi-
rometry and plethysmography), imaging methods (chest radio-
graphs, scintigraphy, and computed tomography ), and more spe-
cific measures (diffusing capacity of the lungs for carbon monoxide,
multiple breath washout, and lung clearance index) provide lim-
ited information about spatial heterogeneity of lung disease and re-
quire either sedation or ionizing radiation. Newer, noninvasive
imaging techniques, such as functional lung imaging with magnetic
resonance imaging, are more sensitive to regional changes within
the lung parenchyma and may provide quantitative information
about both normal and abnormal lung structure and function.7,8
Functional lung imaging with magnetic resonance imaging has sev-
eral advantages; it is safe, requires no ionizing radiation, and pro-
vides a detailed spatial and temporal resolution to evaluate lung
anatomy (airways and parenchyma) and function (regional deliv-
ery of gas or blood) using gas agents. Functional lung imaging could
be used for longitudinal studies of growth and development of the
parenchyma and airways.7,8
Dynamic molecular analyses of the human lung are limited by
tissue availability, but developmental studies using lung tissue when
available and animal models have implemented lung mapping to
identify complex networks of genes and transcriptional factors that
mediate cell differentiation during lung morphogenesis, injury, and
repair9 (see also http://lungmap.org). In the future, these (and other)
novel imaging techniques may provide an approach to better un-
derstand the function of individual cells within lung tissue, exam-
ine specific functions of these cells, including gene expression, and
determine the influence of exposures (eg, antenatal corticoste-
roids) at the cellular level.
Pregnancy Abnormalities That Disturb
Lung Development
Although neonates born very preterm before 34 weeks have the high-
est likelihood of developing respiratory morbidity after birth, these
very preterm infants represent only a small fraction of all babies cared
for in neonatal intensive care units annually in the United States. Neo-
nates born early term (37-38 weeks’ gestation) or late preterm (34-36
weeks’ gestation) represent the largest proportion of babies in neo-
natal intensive care units. These infants have a significantly higher
Figure. Preconceptional, Fetal, and Early Childhood Factors That Influence Lung Growth and Development
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incidence of almost all adverse respiratory morbidities (including re-
spiratory distress syndrome, transient tachypnea of the newborn,
pneumonia, respiratory failure, need for surfactant, and mechanical
ventilation) compared with those born at 39 weeks and beyond.10 To-
disco et al11 assessed lung function at a mean age of 12.5 years among
former late preterm children (none of whom had respiratory morbid-
ity at birth) and found decreased lung function compared with
matched siblings delivered at term, suggesting that differences per-
sist at least into childhood. Recent efforts focused on obstetric qual-
ity improvement have resulted in a significant shift in delivery gesta-
tional age at or beyond 39 weeks’ gestation.12 Even so, many term and
preterm neonates experience respiratory morbidities that are diffi-
cult to predict, and many may eventually develop respiratory mor-
bidities later in childhood and as adults.
Increasingly, researchers and clinicians are appreciating that
some of this variation in outcome may be explained by the intra-
uterine environment and delivery conditions, even when delivery
occurs at full term. Specifically, whether the delivery is indicated (eg,
an induction for maternal reasons such as preeclampsia) or spon-
taneous (eg, due to onset of contractions and cervical change) may
affect the likelihood of adverse respiratory outcomes.10 Like pre-
eclampsia, there are a number of potential maternal medical con-
ditions that can contribute to the development of specific respira-
tor y morbidit ies; respirator y distress syndrome and
bronchopulmonary dysplasia (BPD) are 2 examples of adverse re-
spiratory outcomes that have been widely studied.13,17 For ex-
ample, in some circumstances, exposure to intrauterine inflamma-
tion in the form of chorioamnionitis may induce lung maturation and
Table. Current Challenges, Research Opportunities, and Priorities Grouped by the 4 Major Focus Areas From the National Heart, Lung,
and Blood Institute Workshop
Section/Focus Area Key Barriers and Challenges Research Opportunities and Priorities
Lung development and function Absence of standard measures for normative trajectories
of lung health throughout development.
Need to better understand the prenatal and early
postnatal stimuli and insults during critical periods of
lung development that affect adult lung structure and
physiology.
Lack of clinically applicable noninvasive technologies to
regionally assess and longitudinally track lung function
and pulmonary vascular development from birth
through early adulthood.
Define healthy lung structure and function from infancy
through early adulthood in highly selected and
well-characterized populations.
Use preconception cohort studies to identify early life
stimuli and insults that affect initial lung health and
delineate the physiological and structural changes to the
developing lung in early adulthood.
Develop noninvasive, clinically applicable imaging
techniques to longitudinally assess anatomical,
physiological, and molecular respiratory mechanisms in
utero and early postnatal life that can also be evaluated
through early adulthood.
Specific examples include magnetic resonance–based
techniques and molecular lung mapping.
Pregnancy abnormalities that disturb
lung development
Imperfect and sometimes inconsistent definitions of
obstetric phenotypes.
Numerous confounding factors that influence postnatal
disease including maternal medical disease; fetal sex
and race/ethnicity must be considered.
Inaccessibility of fetal and neonatal lung tissues for
direct sampling and study.
Associate lung outcomes with obstetric determinants
(maternal and/or obstetric complications) as well as
gestational age or birth weight.
Clearly define gestational age and fetal growth restriction.
Better characterize the specific obstetric indications for
dealing with neonatal pulmonary morbidities, in part by
developing prebirth cohorts that detail obstetric
phenotypes.
Evaluate chronic lung disease throughout life based on
delivery indication and factors present during pregnancy
and/or at the time of delivery.
Determine whether decline in lung function with age is
influenced by early term or late preterm birth or specific
fetal exposures.
Advance the use of fetal lung imaging by magnetic
resonance imaging and ultrasonography to assess
pulmonary maturity.
Evaluate the role of the placenta in pregnancy
complications, which may affect fetal lung function.
Develop surrogate markers for fetal/neonatal lung injury.
Developmental programming of lung Lack of information about the role of fetal and early
childhood lung microbiome and little understanding of
the modifiers that may affect disease.
Unknown effect of other tissues or organ systems on
lung development.
Lack of clinically relevant longitudinal biomarkers of
fetal and early childhood lung health.
Limited understanding of how in utero and postnatal
nutritional environments affect lung development or
what the ideal nutritional environment should be to
optimize outcomes.
Delineate the association between maternal, fetal, and
placental immunity, including the role of the fetal
microbiome in normal and abnormal lung development.
Discover biomarkers (from maternal blood, amniotic fluid,
and/or cord blood) to serve as proxies for fetal lung
growth and/or development and identify crucial windows
of immune development or microbial exposure.
Investigate the influence of the intestinal microbiome on
host responses for establishing lung health and disease.
Optimize maternal nutrition to properly modulate healthy
lung development and mediate disease susceptibility.
Environmental interactions and
exposures (maternal, fetal, and infant)
Limited understanding of the mechanisms by which
environmental exposures cause injury and alter
phenotypes in some individuals.
Unknown influence of the airway microbiome during
development.
Uncertain information regarding optimal vitamin
dosage, source, form, and timing of supplementation.
Limited tissue availability to examine underlying genetic
and molecular mechanisms.
Determine the ideal regimen of vitamin supplementation
to reduce the risk of asthma and other adverse early
childhood lung outcomes among those at highest risk
(eg, offspring of smokers and late preterm infants).
Investigate the role of epigenetic modification in
mediating effects of nicotine, air pollution, and other
environmental toxins.
Determine whether epigenetic changes can be
reprogrammed after birth to correct, alter, or compensate
for fetal lung programming in response to environmental
exposures.
Evaluate the effects of increasingly available maternal
products (eg, electronic cigarettes and marijuana) on the
developing lung.
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favorable respiratory outcomes, while in other circumstances, the
same insult may cause acute lung inflammation and injury, result-
ing in severe BPD.13 The reasons for this variable response are un-
known but are likely due to a complex interplay of oxygen expo-
sures, nutrition, and exposure to other postnatal supportive
interventions, which can affect BPD. In other studies, intrapartum
chorioamnionitis has been associated with an increased risk for child-
hood asthma.14 Babies who are growth restricted or small for ges-
tational age are also at elevated risk for developing both respira-
tory distress syndrome and BPD.15,16 Clear definitions of fetal growth
restriction and gestational age are important for newborn assess-
ment and classification. Finally, it is not unexpected that preeclamp-
sia is also independently associated with an elevated risk for BPD,
given that this pregnancy complication is closely related to early on-
set and severe fetal growth restriction in many situations, and both
conditions seem to have placental origins.17 Indeed, abnormal pla-
cental histopathology indicating maternal vascular underperfusion
has been associated with the development of BPD.18
One additional challenge when investigating the effect of the
prenatal period on fetal lung development is the inability to di-
rectly study the fetal human lung. Animal models in combination with
surrogate markers of lung injury (eg, vascular endothelial growth fac-
tor and soluble fms-like tyrosine kinase-1) from maternal blood, am-




Recently, significant attention across multiple disciplines and or-
gan systems has focused on the importance of the microbiome in
determining health and disease and the importance of these mi-
crobes in developmental programming. The respiratory system is no
exception. A unique steady-state microbiota exists in the lungs, and
colonization of the airways provides crucial signals for local im-
mune cell maturation.21 Microbial exposure from the interaction of
the maternal-placental-fetal unit, the route of birth, or even intes-
tinal microbiota can alter the collective genome of the lung micro-
biota and shape lung trajectory toward or away from disease later
in life.22
The placenta is no longer considered a sterile organ, and the
effect of maternal-fetal microbiomes on long-term respiratory out-
comes is an area of ongoing investigation.23-25 In animal models,
modest lung airway and vascular injuries are induced by chorioam-
nionitis, and this injury is directly and indirectly linked to lung
development and growth pathways.13,23 Under normal circum-
stances, bacteria establish clinically occult reservoirs in the
maternal-placental-fetal interface, which harbors a unique micro-
biome composed of “housekeeping” or nonpathogenic
microbiota.24,25 The placenta can house these microbes and pre-
vent them from mounting an immune response that could lead to
adverse pregnancy or fetal outcomes. Thus, the balance of house-
keeping and pathogenic microorganisms, rather than the absolute
presence of any microbes, is key in determining the development
of disease. Although the modulation of inflammation at the maternal-
fetal interface is likely an important driver of fetal outcomes, the
mechanisms are largely unknown.
Microorganisms from the gut can also influence the lung micro-
biome. Animal studies have suggested an association between gut
microbiota, immune regulation, and lung health, recently termed the
gut-lung axis.22 Marsland and Gollwitzer22 demonstrated in a mouse
model that early life multibacterial stimuli in the gut altered a vari-
ety of cellular mediators of pulmonary immunity. Although there is
ongoing work in humans to evaluate associations between the iden-
tity of specific enteric microbiome signatures and lung develop-
ment in premature infants, limited studies exist on term and late pre-
term infants.26 Although composition of the intestinal microbiota
stabilizes with age, there may be a simultaneous seeding of lung and
intestinal microbiota during the critical window of lung develop-
ment, and several factors, such as antibiotic therapy, infectious
agents, and nutritional supplements, may also modulate the
airway microbiota.22
In addition to the microbiome, maternal nutrition is a signifi-
cant contributor to developmental programming and lung devel-
opment. Maternal diet during pregnancy modulates healthy lung de-
velopment and mediates disease susceptibility. The Barker27
hypothesis proposes that fetal undernutrition in middle to late ges-
tation leads to disproportionate fetal growth and induces perma-
nent changes in body structure. Indeed, protein deprivation during
pregnancy increases bronchial reactivity in human studies28 and
leads to sustained impairment of alveolarization in animal models.29
In contrast, maternal high-fat diet exposure in utero induces an ag-
gravated inflammatory cell recruitment effect in the fetal lung and
promotes lung tissue remodeling in rat models.30 Evidence is also
accumulating that both maternal nutrition prior to and at concep-
tion and environmental factors during early life have long-term ef-
fects on later health outcomes; these processes likely reflect devel-
opmental programming responses to periconceptional exposures.31
Environmental Interactions and Exposures
There are multiple opportunities during the antenatal and imme-
diate postnatal periods for environmental exposures that may
directly or indirectly influence lung health outcomes among
infants born at any gestational age. These include maternal gesta-
tional diabetes mellitus, medication or drug exposure during
pregnancy, peripartum infection, cesarean delivery (with possible
resultant effect on the diversity of the lung microbiome), postna-
tal exposure to oxygen, and postnatal initiation of positive pres-
sure ventilation.
One well-studied exposure is cigarette smoke, which has sig-
nificant effects on developing lungs. Antenatal exposure (irrespec-
tive of postnatal exposure) doubles the risk of childhood asthma,
increases the risk for sudden infant death syndrome, thickens air-
ways and vascular walls, and may permanently alter alveolar and air-
way geometry.32,33 Maternal smoking may lead to a lifelong de-
crease in forced expiratory flows, with changes into adulthood.
Animal and human studies suggest that vitamin C supplementa-
tion (an antioxidant) provided to maternal smokers during preg-
nancy may block some in utero effects of nicotine and improve lung
function among newborn infants.32,33 However, the long-term ef-
fects of this supplementation are largely unknown. This is a prime
example of how one adverse environmental exposure can be
potentially abrogated by an additional positive exposure.
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Other studies examining the effects of various vitamin supple-
ments during pregnancy and early childhood on lung function have
had mixed results. To our knowledge, there are few studies of vita-
min supplementation of pregnant women related to lung health in off-
spring and even fewer of pregnant smokers. Vitamin A is thought to
regulate lung growth through cell proliferation and differentiation; im-
proved lung function was observed among offspring when under-
nourished pregnant women received vitamin A supplementation.34
In an experimental animal model, maternal vitamin D deficiency in-
creased offspring airway smooth muscle mass, baseline airway resis-
tance, inflammation, and altered postnatal lung structure and func-
tion, suggesting a critical window for vitamin D replacement.35
Similarly in humans, vitamin D deficiency during in utero lung devel-
opment resulted in decreased forced vital capacity z scores in child-
hood and early adolescence.36 Reduced vitamin E levels in maternal
blood in the first and second trimesters among infants with intrauter-
ine growth restriction was associated with reduced lung function at
5 years of age and an increased risk of asthma.37 Thus, the optimal
doses of vitamin supplementations may need to be reexamined, par-
ticularly during pregnancy. Doubts regarding the optimal level of nu-
trients, the ideal source of supplementation (from food vs pills), and
the best timing to provide the supplementation (prenatal, postnatal,
or both) abound. It is also unclear whether individuals who are nutri-
ent replete need supplementation.
The mechanisms by which these positive (eg, vitamin expo-
sure) and negative (eg, nicotine) environmental stimuli influence lung
development are incompletely understood. Basic science research has
attempted to investigate the underlying causative mechanisms by
which these exposures alter the normal course of development. Epi-
genetic changes in gene expression can explain phenotypic varia-
tion caused by environmental factors. Therefore, epigenetic analysis
may provide clues to the potential etiologies behind human disease,
including lung disease. Both developmental (patterns of gene expres-
sion independent of the environment) and environmental (patterns
of gene expression that vary depending on the environment) epigen-
etics can affect the regulation of transcription and can also affect non-
coding regions of the genome. While studies have suggested a role
for epigenetics in nearly all disease processes, most research has dem-
onstrated only association, not causation. Additional work is needed
to determine the underpinnings of disease at the molecular level and
the influence of environmental exposures on gene expression, which
may lead to new therapeutic strategies.
Conclusions and Final Recommendations
There are multiple opportunities to address the specific research pri-
orities outlined in the Table. It is clear that future investigations will
need not only to examine abnormal lung development, but also to
use developing technology and resources to better define normal.
Some proportion of future studies will need to use birth cohorts to
capture the important influence of preconception and obstetric risk
factors on lung health, development, and disease. It is imperative
that these birth cohorts include well-characterized obstetrical data,
with comprehensive plans for prospective follow-up. On the other
hand, the importance of continued basic science, translational, and
animal studies cannot be overemphasized, particularly as these data
may provide more immediate answers regarding causality. Multi-
disciplinary approaches with obstetricians, neonatologists, pediat-
ric and adult pulmonologists, epidemiologists, and basic scientists
are essential for the comprehensive research needed to advance the
understanding of lung development across a lifetime.
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